Form 4: Dare Bioscience Director Jessica D. Grossman Granted Stock Options

Dare Bioscience, Inc. director Jessica D. Grossman was granted 4,500 stock options with an exercise price of $2.44, set to vest on the earlier of the first anniversary of the grant date or prior to the company's first annual meeting of stockholders after the grant.

Summary

• Jessica D. Grossman, a Director of Dare Bioscience, Inc. (DARE), was granted 4,500 stock options.
• The options have an exercise price of $2.44 per share.
• The grant date for these options is July 9, 2025.
• The options will vest in full on the earlier of July 9, 2026 (the first anniversary of the grant date) or immediately prior to Dare Bioscience's first annual meeting of stockholders occurring after the grant date.
• Vesting is subject to Ms. Grossman's continued service as a director.
• The options will become exercisable in full immediately upon a change in control of the issuer.
• The expiration date for these stock options is July 9, 2035.
• Following this transaction, Ms. Grossman beneficially owns 4,500 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While a routine compensation event, it signifies continued alignment of a director's interests with the company's long-term performance and shareholder value, which is generally viewed favorably.

Positives

• The grant of stock options aligns the interests of Director Jessica D. Grossman with those of the shareholders, as the value of the options increases with the company's stock price.
• This is a standard form of equity compensation for directors, indicating a commitment to retaining experienced board members.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, though this is a common aspect of equity compensation plans.

Future Outlook

The stock options granted to Director Jessica D. Grossman are set to vest on the earlier of July 9, 2026, or immediately prior to the company's first annual meeting of stockholders after the grant date, subject to her continued service. The options will also accelerate vesting upon a change in control of the issuer.

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology, as a means of compensation and to incentivize long-term performance and alignment with shareholder interests. This practice is consistent with typical corporate governance structures for publicly traded companies.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a widely accepted practice in the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Pfizer, Johnson & Johnson, or smaller biotech firms, which often include equity components to align director incentives with company performance.
• The vesting schedule, tied to continued service and potential acceleration upon a change in control, is also a standard feature in many executive and director equity compensation plans across the industry.

Related Party Transactions

• The grant of stock options to Jessica D. Grossman, a Director of Dare Bioscience, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from aligned interests between the director and company performance.
• Director (Jessica D. Grossman): Receives equity compensation, aligning her financial interests with the company's success and providing an incentive for continued service.

Next Steps

• The stock options will vest on the earlier of July 9, 2026, or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, contingent on continued service.
• The options may become exercisable earlier upon a change in control of Dare Bioscience, Inc.
• The options will expire on July 9, 2035, if not exercised.

Key Dates

Keywords

Dare Bioscience, DARE, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Corporate Governance